Kemali / Bartholini / Richter Schizophrenia Today

1. Auflage 2013
ISBN: 978-1-4831-5298-1
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 298 Seiten, Web PDF

Schizophrenia Today is a collection of papers presenting conflicting viewpoints on schizophrenia and some focal subjects for future research. The book deals with the definition of schizophrenia and presents various advances in understanding the condition. The text surveys the problems of epidemiology and symptomatology in terms of the etiology and pathogenesis of schizophrenia. Several papers present the societal and cultural aspects of the problem on issues of clinical overview; international collaboration in schizophrenia research; and the societal determinants of schizophrenic behavior. Other papers then discuss the genetic and biochemical approaches in dealing with schizophrenia. One paper concludes that genetic factors play a significant role in the etiology of schizophrenia. The text also reviews the studies conducted by Rolf Gjessing, establishing that mood changes in mental state are related to changes in autonomic activity, metabolic rate, and nitrogen balance. The book also discusses the pharmacological and psychotherapeutic approaches in treating the problem. One paper deals with the personal experience of the writer in using psychoanalysis for treating schizophrenia. The collection will prove valuable for psychiatrists, psychologists, psychoanalysts, and students and researchers dealing with mental diseases.

Autoren/Hrsg.

Kemali, D.

Bartholini, G.

Richter, D.

Inhaltsverzeichnis

1;Front Cover;1
2;Schizophrenia Today;4
3;Copyright Page;5
4;Table of Contents;6
5;List of Participants;8
6;Poster Exhibition;14
7;Foreword;15
8;Opening Address;16
9;SESSION 1: Societal and Cultural Aspects;18
9.1;Chapter 1. Definition, Classification and Nomenclature: A Clinical Overview;20
9.1.1;References;28
9.2;Chapter 2. International Collaboration in Schizophrenia Research;30
9.2.1;Collaboration in Schizophrenia Research;31
9.2.2;The Need for a Common Language;31
9.2.3;The International Pilot Study of Schizophrenia (IPSS);32
9.2.4;Directions of Future Work;36
9.2.5;References;38
9.3;Chapter 3. Societal Determinants of Schizophrenic Behaviour;40
9.3.1;Schizophrenic Behavior;40
9.3.2;Societal Variables Influencing Behavior;41
9.3.3;Social Change: Migration;49
9.3.4;Psychosocial Events Correlated with the Occurrence of Schizophrenic Behavior;52
9.3.5;Integration: Society, Events, Behavior;57
9.3.6;Summary;61
9.3.7;References;63
10;SECTION 2: Genetic and Biochemical Approaches;66
10.1;Chapter 4. The Contribution of Genetics and Biochemistry: Chairman's Opening Remarks;68
10.1.1;References;72
10.2;Chapter 5. Genetics in Schizophrenia;74
10.2.1;Historical Review of the Genetic Hypothesis;74
10.2.2;Unity or Diversity of the Schizophrenic Syndromes;78
10.2.3;Mode of inheritance;79
10.2.4;Nature of the Principal Factors;82
10.2.5;Summary;83
10.2.6;References;84
10.3;Chapter 6. The Impact of Biochemistry on the Problem of Schizophrenia;88
10.3.1;1. The Neurological Basis of the Symptoms;88
10.3.2;2. Toxic Metabolite Hypotheses;89
10.3.3;3. Blood Proteins;91
10.3.4;4. Genetic Predisposition;91
10.3.5;5. Environmental Factors;93
10.3.6;6. The Focus of Disturbance in Schizophrenia;94
10.3.7;7. Central Transmitter Mechanisms in Schizophrenia;96
10.3.8;8. Periodic Catatonia;97
10.3.9;References;99
11;SESSION 3: Pharmacological Approaches;102
11.1;Chapter 7. Introductory Remarks;104
11.2;Chapter 8. The Impact of Pharmacology on the Problem of Schizophrenia;106
11.2.1;Introduction;106
11.2.2;Discovery of Dopamine, an Endogenous Agonist in the Brain;106
11.2.3;Brain Monoamines: Neurohumoral Transmitters;107
11.2.4;Receptor-Blocking Antipsychotic Agents;107
11.2.5;Role of Different Dopaminergic Pathways;110
11.2.6;Antipsychotic Action of a Tyrosine Hydroxylase Inhibitor;111
11.2.7;The Nature of Antipsychotic Drug Effect;113
11.2.8;Amphetamines and Schizophrenia;115
11.2.9;The Possible Role of GABA in Schizophrenia;115
11.2.10;Concluding Remarks;117
11.2.11;References;118
11.3;Chapter 9. Drug-induced Psychoses and their Relationship to Schizophrenia;122
11.3.1;Introduction;122
11.3.2;I. Psychotomimetic Drugs (Hallucinogens);124
11.3.3;II. Amphetamines and Related Substances;133
11.3.4;III. Ethyl Alcohol;136
11.3.5;IV. Miscellaneous Drugs;138
11.3.6;References;143
11.4;Chapter 10. On the Biochemistry and Pharmacology of Hallucinogens;152
11.4.1;Central 5-HT neurons;153
11.4.2;Effects on Central DA Neurons;166
11.4.3;Summary;171
11.4.4;Acknowledgements;172
11.4.5;References;173
12;SESSION 4: Neuroleptic Drugs;176
12.1;Chapter 11. The Drug Approach to Therapy. Treatment of Acute Schizophrenia;178
12.1.1;I. Guides to Classification;178
12.1.2;II. Assessment and Treatment;180
12.1.3;III. Prognostic Aspects;184
12.1.4;References;186
12.2;Chapter 12. The Drug Approach to Therapy. Long-term Treatment of Schizophrenia;190
12.2.1;Etiology of Schizophrenia;190
12.2.2;Classification of Antipsychotic Drugs;190
12.2.3;General Rules for Long-term Treatment;193
12.2.4;Antiparkinsonian Treatment;193
12.2.5;Tardive Dyskinesia in Relation to Long-term Treatment;194
12.2.6;Results of Treatment;195
12.2.7;New Drugs and Drugs of the Future;196
12.2.8;Discussion;197
12.2.9;References;198
12.3;Chapter 13. Neuroleptic Drugs. Chemical versus Biochemical Classification;200
12.3.1;1. Chemical Classification;200
12.3.2;2. Biochemical Classification;209
12.3.3;3. Relation Between Chemical and Biochemical Classification;214
12.3.4;4. Summary;214
12.3.5;Acknowledgement;215
12.3.6;References;216
13;SESSION 5: Physiological and Psychological Findings;218
13.1;Chapter 14. Novel Neurophysiological Findings in Schizophrenia;220
13.1.1;I. Introduction;220
13.1.2;II. EEG in Adult Schizophrenics;220
13.1.3;III. Computer EEG in Schizophrenic Children;222
13.1.4;IV. CEEG Finding in Children at "high risk" for Schizophrenia;222
13.1.5;V. Summary and Conclusion;225
13.1.6;References;227
13.2;Chapter 15. Basic Logico-mathematical Structures in Schizophrenia;228
13.2.1;I. Types of Symptoms in Schizophrenia;228
13.2.2;II. Manifestations of Schizophrenia Viewed in the Light of Symbolic Logic;228
13.2.3;III. Subsequent Studies. The Two Modes of Being and the Bi-logical Structures;240
13.2.4;IV. Schizophrenic Bi-logical Structures;247
13.2.5;References;250
14;SESSION 6: Psychotherapeutic Approaches;252
14.1;Chapter 16. Some Aspects of Cognitive Activities in Schizophrenics;254
14.1.1;Methods;255
14.1.2;Results;255
14.1.3;References;261
14.2;Chapter 17. The Psychotherapeutic Approach to Schizophrenia;262
14.2.1;Historical Review of the Theoretical Bases of the Main Methods;263
14.2.2;Psychotherapy of Schizophrenia in Practice;266
14.2.3;The Acquisition of Insight;267
14.2.4;Interpretations Concerning the Formal Mechanisms;268
14.2.5;Psychodynamic Analysis;270
14.2.6;References;273
14.3;Chapter 18. The Treatment of Psychotic States, Particularly Schizophrenia, by Psychoanalysis;276
14.3.1;Notes on my Experiences with Psychotherapy and Psychoanalysis of Psychotic Patients;277
14.3.2;Comparisons Between Different Psychoanalytic Approaches;279
14.3.3;Some Recent Investigation of the Narcissistic Delusional Structures in Schizophrenia;280
14.3.4;References;285
15;SESSION 7: Synthesis and Concluding Remarks;288
15.1;Chapter 19. Recent Contributions from the basic Biological Sciences toward an understanding of Schizophrenia;290
15.2;Chapter 20. Clinical Sciences;292
16;Index;296